| Abstract: |
The monoclonal antibody 3F8 has been described as binding to the ganglioside GD2. This antibody, of the IgG3 isotype, has been used in immunotherapy, radioimmunolocalisation and targeted radiation therapy. 3F8 was originally observed to have a binding profile similar to two monoclonal antibodies, UJ13A and 5.1.H11, characterised as binding to the neural cell adhesion molecule (NCAM). This observation has also been confirmed using a hetero-antiserum prepared against purified NCAM. The cross-reactivity of 3F8 with NCAM has been confirmed by cross-blocking studies with an anti-NCAM antiserum, and by direct immunoprecipitation and gel electrophoresis. In addition, we show that 3F8 binds to human NCAM from 3T3 fibroblasts transfected with NCAM cDNA constructs. It is possible that the common epitope shared by GD2 ganglioside and NCAM involves sialic acid residues common to both the ganglioside and the glycoprotein. © The Macmillan Press Ltd., 1989. |
| Keywords: |
adult; unclassified drug; human cell; comparative study; cell line; tumor cells, cultured; monoclonal antibody; antibodies, monoclonal; genetic engineering; cell culture; ganglioside gd2; nerve cell adhesion molecule; cytochemistry; monoclonal antibody 3f8; epitopes; gangliosides; binding, competitive; cross reactions; dna transfection; human; priority journal; article; cell adhesion molecules, neuronal; support, non-u.s. gov't
|
